238 related articles for article (PubMed ID: 34332136)
21. Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection.
Chan KM; Kuo CF; Hsu JT; Chiou MJ; Wang YC; Wu TH; Lee CF; Wu TJ; Chou HS; Lee WC
Liver Int; 2017 Mar; 37(3):434-441. PubMed ID: 27775209
[TBL] [Abstract][Full Text] [Related]
22. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
Arvind A; Memel ZN; Philpotts LL; Zheng H; Corey KE; Simon TG
Metabolism; 2021 Jul; 120():154780. PubMed ID: 33891949
[TBL] [Abstract][Full Text] [Related]
23. Association Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer.
Yao K; Zheng H; Li T
Front Oncol; 2022; 12():942380. PubMed ID: 35898873
[TBL] [Abstract][Full Text] [Related]
24. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.
Lai SW; Chen PC; Liao KF; Muo CH; Lin CC; Sung FC
Am J Gastroenterol; 2012 Jan; 107(1):46-52. PubMed ID: 22085817
[TBL] [Abstract][Full Text] [Related]
25. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.
Tseng CH
Liver Int; 2018 Nov; 38(11):2018-2027. PubMed ID: 29956875
[TBL] [Abstract][Full Text] [Related]
26. Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis.
Wang J; Li X
Eur J Gastroenterol Hepatol; 2021 Dec; 33(12):1603-1609. PubMed ID: 33405428
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies.
Yang J; Yang H; Cao L; Yin Y; Shen Y; Zhu W
Medicine (Baltimore); 2022 Dec; 101(49):e31799. PubMed ID: 36626437
[TBL] [Abstract][Full Text] [Related]
28. Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Nie SP; Chen H; Zhuang MQ; Lu M
Asian Pac J Cancer Prev; 2014; 15(16):6863-9. PubMed ID: 25169538
[TBL] [Abstract][Full Text] [Related]
29. Metformin Use Is Associated with Reduced Incidence and Improved Survival of Endometrial Cancer: A Meta-Analysis.
Tang YL; Zhu LY; Li Y; Yu J; Wang J; Zeng XX; Hu KX; Liu JY; Xu JX
Biomed Res Int; 2017; 2017():5905384. PubMed ID: 28409158
[TBL] [Abstract][Full Text] [Related]
30. Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis.
Zhang M; He JQ
Eur J Clin Pharmacol; 2020 Feb; 76(2):149-159. PubMed ID: 31786617
[TBL] [Abstract][Full Text] [Related]
31. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.
Schulte L; Scheiner B; Voigtländer T; Koch S; Schweitzer N; Marhenke S; Ivanyi P; Manns MP; Rodt T; Hinrichs JB; Weinmann A; Pinter M; Vogel A; Kirstein MM
Liver Int; 2019 Apr; 39(4):714-726. PubMed ID: 30663219
[TBL] [Abstract][Full Text] [Related]
32. Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis.
Ma SJ; Zheng YX; Zhou PC; Xiao YN; Tan HZ
Oncotarget; 2016 Oct; 7(40):66202-66211. PubMed ID: 27494848
[TBL] [Abstract][Full Text] [Related]
33. Association of Preadmission Metformin Use and Prognosis in Patients With Sepsis and Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Li Y; Zhao H; Guo Y; Duan Y; Guo Y; Ding X
Front Endocrinol (Lausanne); 2021; 12():811776. PubMed ID: 35002982
[TBL] [Abstract][Full Text] [Related]
34. The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes mellitus: A meta-analysis.
Xiao K; Liu F; Liu J; Xu J; Wu Q; Li X
J Clin Pharm Ther; 2020 Aug; 45(4):783-792. PubMed ID: 32406122
[TBL] [Abstract][Full Text] [Related]
35. Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma.
Zhou YY; Zhu GQ; Liu T; Zheng JN; Cheng Z; Zou TT; Braddock M; Fu SW; Zheng MH
Sci Rep; 2016 Sep; 6():33743. PubMed ID: 27642100
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients.
Ma S; Zheng Y; Xiao Y; Zhou P; Tan H
Medicine (Baltimore); 2017 May; 96(19):e6888. PubMed ID: 28489794
[TBL] [Abstract][Full Text] [Related]
37. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer.
Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Fajkovic H; Babjuk M; Kautzky-Willer A; Bachmann A; Scherr DS; Shariat SF
BJU Int; 2013 Dec; 112(8):1105-12. PubMed ID: 24053906
[TBL] [Abstract][Full Text] [Related]
38. Asarone and metformin delays experimentally induced hepatocellular carcinoma in diabetic milieu.
Das BK; Choukimath SM; Gadad PC
Life Sci; 2019 Aug; 230():10-18. PubMed ID: 31121175
[TBL] [Abstract][Full Text] [Related]
39. Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis.
Wang YG; Wang P; Wang B; Fu ZJ; Zhao WJ; Yan SL
PLoS One; 2014; 9(5):e95485. PubMed ID: 24830459
[TBL] [Abstract][Full Text] [Related]
40. Metformin therapy associated with survival benefit in lung cancer patients with diabetes.
Wan G; Yu X; Chen P; Wang X; Pan D; Wang X; Li L; Cai X; Cao F
Oncotarget; 2016 Jun; 7(23):35437-45. PubMed ID: 27105507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
